EIKON THERAPEUTICS, INC. Research and Development Expense
EIKON THERAPEUTICS, INC. (EIKN) reported Research and Development Expense of $75.46 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-13
- EIKON THERAPEUTICS, INC. research and development expense for the quarter ending 2026-06-30 was $75.46M, a 9.06% increase year-over-year.
- EIKON THERAPEUTICS, INC. research and development expense for the quarter ending 2026-03-31 was $70.05M, a 23.79% increase year-over-year.
- EIKON THERAPEUTICS, INC. research and development expense for the quarter ending 2025-06-30 was $69.19M.
- EIKON THERAPEUTICS, INC. research and development expense for the quarter ending 2025-03-31 was $56.59M.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month |
|---|---|---|
| 2026-06-30 | $75.46M 10-Q · filed 2026-08-13 | $145.51M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $70.05M 10-Q · filed 2026-05-11 | |
| 2025-06-30 | $69.19M 10-Q · filed 2026-08-13 | $125.78M 10-Q · filed 2026-08-13 |
| 2025-03-31 | $56.59M 10-Q · filed 2026-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |